**Merck and Moderna maintain a decade-long partnership on their individualized neoantigen therapy intismeran autogene (mRNA-4157/V940) combined with Keytruda, recently bolstered by positive Phase 3 INTerpath-001 results in August 2026 showing statistically significant improvements in recurrence-free and distant metastasis-free survival for resected melanoma.** This success, which drove sharp gains in Moderna shares, has reinforced their existing cost- and profit-sharing arrangement without prompting acquisition discussions. Merck has pursued separate oncology deals, including the Terns Pharmaceuticals acquisition earlier in 2026, while Moderna advances its independent pipeline and commercialization preparations via a new October 2026 Tempus collaboration. Trader consensus at 90.1% against a 2026 announcement reflects these dynamics and the absence of regulatory or financial catalysts that would typically drive consolidation. A sudden shift could occur if post-Keytruda loss-of-exclusivity pressures or major new data alter strategic priorities, though current evidence points to continued arm’s-length cooperation.